Par le Pr Steve Conlan
Université de Médecine de Swansea, Pays de Galles
Ovarian cancer has a specific unmet clinical need, with a persistently poor 5-year survival rate observed in women with advanced stage disease warranting continued efforts to develop new treatment options. Here I will discuss our recent approaches to identifying, developing and evaluating a number of potential therapeutic approaches including Antibody Drug Conjugates, BET inhibitors, selenium nanoparticles and other molecules identified through in silico approaches. I will also discuss our recent advances in cancer immune profiling, and diagnostics, facilitated by emerging genomic technologies.
R. Steven Conlan est PhD FRSB
Professeur en biologie moléculaire et cellulaire
Président de la Société britannique de nanomédecine
Co-vice-président de la plateforme technologique européenne - Nanomédecine
Ambassadeur STEM